TWIST1 Gene expression as a biomarker for predicting primary doxorubicin resistance in breast cancer

1World Health Organization (https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/). World Health Organization https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/Search in Google Scholar

2Filipova A, Seifrtova M, Mokry J, Dvorak J, Rezacova M, Filip S, et al. Breast cancer and cancer stem cells: A mini-review. Tumori. 2014; 100(4): 363-369. Filipova A Seifrtova M Mokry J Dvorak J Rezacova M Filip S et al Breast cancer and cancer stem cells: A mini-review Tumori 2014 1004 363 36910.1177/1636.17886Search in Google Scholar

3Dörfel S, Steffens CC, Meyer D, Tesch H, Kruggel L, Frank M, et al. Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: Data from the prospective TMK cohort study. Breast Cancer. 2018; 25(3): 275-283. Dörfel S Steffens CC Meyer D Tesch H Kruggel L Frank M et al Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: Data from the prospective TMK cohort study Breast Cancer 2018 253 275 28310.1007/s12282-017-0823-7590652329204847Search in Google Scholar

4Ribeiro JT, Macedo LT, Curigliano G, Fumagalli L, Locatelli M, Dalton M, et al. Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: Back to the future? Ann Oncol. 2012; 23(3): 547-555. Ribeiro JT Macedo LT Curigliano G Fumagalli L Locatelli M Dalton M et al Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: Back to the future? Ann Oncol 2012 233 547 55510.1093/annonc/mdr38221896541Search in Google Scholar

5Duffy MJ, O’Donovan N, McDermott E, Crown J. Validated biomarkers: The key to precision treatment in patients with breast cancer. Breast. 2016; 29: 192-201. Duffy MJ O’Donovan N McDermott E Crown J Validated biomarkers: The key to precision treatment in patients with breast cancer Breast 2016 29 192 20110.1016/j.breast.2016.07.00927521224Search in Google Scholar

6Online Mendelian Inheritance in Man, OMIM^® Mc-Kusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, MD, USA (https://omim.org/). Online Mendelian Inheritance in Man, OMIM^® Mc-Kusick-Nathans Institute of Genetic Medicine Johns Hopkins University Baltimore, MD, USA https://omim.org/Search in Google Scholar

7Pajer P, Pecenka V, Karafiát V, Králová J, Horejsí Z, Dvorák M. The twist gene is a common target of retroviral integration and transcriptional deregulation in experimental nephroblastoma. Oncogene. 2003; 22(5): 665-673. Pajer P Pecenka V Karafiát V Králová J Horejsí Z Dvorák M The twist gene is a common target of retroviral integration and transcriptional deregulation in experimental nephroblastoma Oncogene 2003 225 665 67310.1038/sj.onc.120610512569359Search in Google Scholar

8Yin G, Chen R, Alvero AB, Fu HH, Holmberg J, Glackin C, et al. TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene. 2010; 29(24): 3545-353. Yin G Chen R Alvero AB Fu HH Holmberg J Glackin C et al TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214 Oncogene 2010 2924 3545 35310.1158/0008-5472.FBCR09-B75Search in Google Scholar

9Tseng JC, Chen HF, Wu KJ. A twist tale of cancer metastasis and tumor angiogenesis. Histol Histopathol. 2015; 30(11): 1283-1294. Tseng JC Chen HF Wu KJ A twist tale of cancer metastasis and tumor angiogenesis Histol Histopathol 2015 3011 1283 1294Search in Google Scholar

10Norozi F, Ahmadzadeh A, Shahjahani M, Sharabi S, Saki N. Twist as a new prognostic marker in hematological malignancies. Clin Transl Oncol. 2016; 18(2): 113-124. Norozi F Ahmadzadeh A Shahjahani M Sharabi S Saki N Twist as a new prognostic marker in hematological malignancies Clin Transl Oncol 2016 182 113 12410.1007/s12094-015-1357-026203802Search in Google Scholar

11Zhao Z, Rahman MA, Chen ZG, Shin DM. Multiple biological functions of Twist1 in various cancers. Oncotarget. 2017; 8(12): 20380-20393. Zhao Z Rahman MA Chen ZG Shin DM Multiple biological functions of Twist1 in various cancers Oncotarget 2017 812 20380 2039310.18632/oncotarget.14608538677028099910Search in Google Scholar

12Qiao W, Jia Z, Liu H, Liu Q, Zhang T, Guo W, et al. Prognostic and clinicopathological value of Twist expression in breast cancer: A meta-analysis. PLoS One. 2017; 12(10): e0186191-e0186202. Qiao W Jia Z Liu H Liu Q Zhang T Guo W et al Prognostic and clinicopathological value of Twist expression in breast cancer: A meta-analysis PLoS One 2017 1210 e0186191 e018620210.1371/journal.pone.0186191563319529016671Search in Google Scholar

13Andreotti PE, Linder D, Hartmann DM, Cree IA, Pazzagli M, Bruckner HW. TCA-100 tumour chemo-sensitivity assay: Differences in sensitivity between cultured tumour cell lines and clinical studies. J Bio-lumin Chemilumin. 1994; 9(6): 373-378. Andreotti PE Linder D Hartmann DM Cree IA Pazzagli M Bruckner HW TCA-100 tumour chemo-sensitivity assay: Differences in sensitivity between cultured tumour cell lines and clinical studies J Bio-lumin Chemilumin 1994 96 373 37810.1002/bio.11700906047879653Search in Google Scholar

14Cree IA, Kurbacher CM, Untch M, Sutherland LA, Hunter EM, Subedi AM, et al. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anticancer Drugs. 1996; 7(6): 630-635. Cree IA Kurbacher CM Untch M Sutherland LA Hunter EM Subedi AM et al Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity Anticancer Drugs 1996 76 630 63510.1097/00001813-199608000-000028913430Search in Google Scholar

15Vogt U, Bielawski KP, Bosse U, Schlotter CM. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep. 2004; 12(5): 1109-1114. Vogt U Bielawski KP Bosse U Schlotter CM Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid Oncol Rep 2004 125 1109 111410.3892/or.12.5.1109Search in Google Scholar

16Kurbacher CM, Cree IA. Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements. Methods Mol Med. 2005; 110: 101-120. Kurbacher CM Cree IA Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements Methods Mol Med 2005 110 101 12010.1385/1-59259-869-2:101Search in Google Scholar

17Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4): 402-408. Livak KJ Schmittgen TD Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method Methods 2001 254 402 40810.1006/meth.2001.126211846609Search in Google Scholar

18Zelnak A. Overcoming taxane and anthracycline resistance. Breast J. 2010; 16(3): 309-312. Zelnak A Overcoming taxane and anthracycline resistance Breast J 2010 163 309 31210.1111/j.1524-4741.2010.00911.x20408821Search in Google Scholar

19Hofmann D, Nitz U, Gluz O, Kates RE, Schin-koethe T, Staib T, et al. WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: Study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial. Trials. 2013; 14: 261. doi: 10.1186/1745- 6215-14-261. Hofmann D Nitz U Gluz O Kates RE Schin-koethe T Staib T et al WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: Study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial Trials 2013 14 261 10.1186/1745-6215-14-261376594023958221Open DOISearch in Google Scholar

20Ayyagari VN, Hsieh TJ, Diaz-Sylvester PL, Brard L. Evaluation of the cytotoxicity of the Bithionolcisplatin combination in a panel of human ovarian cancer cell lines. BMC Cancer. 2017; 17(1): 49. Ayyagari VN Hsieh TJ Diaz-Sylvester PL Brard L Evaluation of the cytotoxicity of the Bithionolcisplatin combination in a panel of human ovarian cancer cell lines BMC Cancer 2017 171 4910.1186/s12885-016-3034-2523411228086831Search in Google Scholar

21Smith SC, Baras AS, Lee JK, Theodorescu D. The COXEN principle: Translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Res. 2010; 70(5): 1753-1758. Smith SC Baras AS Lee JK Theodorescu D The COXEN principle: Translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer Cancer Res 2010 705 1753 175810.1158/0008-5472.CAN-09-3562283113820160033Search in Google Scholar

22Wang LF, Yin HT, Qian XP, Wei J, Zhao Y, Yu LX, et al. Beta-Tubulin III mRNA expression and docetaxel sensitivity in non-small cell lung cancer. Clin Invest Med. 2009; 32(6): E278-E284. Wang LF Yin HT Qian XP Wei J Zhao Y Yu LX et al Beta-Tubulin III mRNA expression and docetaxel sensitivity in non-small cell lung cancer Clin Invest Med 2009 326 E278 E28410.25011/cim.v32i6.1066320003833Search in Google Scholar

23Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, et al. Twist is a potential oncogene that inhibits apoptosis. Genes Dev. 1999; 13(17): 2207-2217. Maestro R Dei TosAP Hamamori Y Krasnokutsky S Sartorelli V Kedes L et al Twist is a potential oncogene that inhibits apoptosis Genes Dev 1999 1317 2207 221710.1101/gad.13.17.220731700410485844Search in Google Scholar

24Pham CG, Bubici C, Zazzeroni F, Knabb JR, Papa S, Kuntzen C, et al. Upregulation of Twist-1 by NF-kappaB blocks cytotoxicity induced by chemotherapeutic drugs. Mol Cell Biol. 2007; 27(11): 3920-3935. Pham CG Bubici C Zazzeroni F Knabb JR Papa S Kuntzen C et al Upregulation of Twist-1 by NF-kappaB blocks cytotoxicity induced by chemotherapeutic drugs Mol Cell Biol 2007 2711 3920 393510.1128/MCB.01219-06190000817403902Search in Google Scholar

25Wang L, Tan RZ, Zhang ZX, Yin R, Zhang YL, Cui WJ, et al. Association between Twist and multidrug resistance gene-associated proteins in Taxol®-resistantMCF-7 cells and a 293 cell model of Twist overexpression. Oncol Lett. 2018; 15(1): 1058-1066. Wang L Tan RZ Zhang ZX Yin R Zhang YL Cui WJ et al Association between Twist and multidrug resistance gene-associated proteins in Taxol®-resistantMCF-7 cells and a 293 cell model of Twist overexpression Oncol Lett 2018 151 1058 1066Search in Google Scholar

26Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, Tang F, et al. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res. 2009; 15(8): 2657-2665. Li QQ Xu JD Wang WJ Cao XX Chen Q Tang F et al Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells Clin Cancer Res 2009 158 2657 266510.1158/1078-0432.CCR-08-237219336515Search in Google Scholar

27Saxena M, Stephens MA, Pathak H, Rangarajan A. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2011; 2: e179-e191. Saxena M Stephens MA Pathak H Rangarajan A Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters Cell Death Dis 2011 2 e179 e19110.1038/cddis.2011.61319972221734725Search in Google Scholar

28Hillen F, Griffioen AW. Tumour vascularization: Sprouting angiogenesis and beyond. Cancer Metastasis Rev. 2007; 26(3-4): 489-502 Hillen F Griffioen AW Tumour vascularization: Sprouting angiogenesis and beyond Cancer Metastasis Rev 2007 263-4 489 50210.1007/s10555-007-9094-7279785617717633Search in Google Scholar

29Flamant L, Roegiers E, Pierre M, Hayez A, Sterpin C, De Backer O, et al. TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells. BMC Cancer. 2012; 12: 391-407. Flamant L Roegiers E Pierre M Hayez A Sterpin C De BackerO et al TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells BMC Cancer 2012 12 391 40710.1186/1471-2407-12-391351960622954140Search in Google Scholar